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CC BY-NC-ND license (http://creativeBackground/Purpose: Chronic pain is a common and important medical problem worldwide.
Patients with chronic intractable noncancer pain (CINCP) are treated primarily with narcotics.
We analyzed the characteristics of patients with CINCP and the pain prescriptions of Taiwan’s
physicians.
Methods: We enrolled 644 patients from 66 hospitals approved by the Taiwan Food and Drug
Administration to use long-term narcotics for CINCP between 2003 and 2012.
Results: The majority (61.8%) of patients were 40e49-year-old men who had been treated with
pethidine more often than with fentanyl in the 20e49 years age group. More than 50% of CINCP
patients live in northern Taiwan, and most were treated in the department of pain; the major
diagnosis (men 28.9%; women 27.7%) was neuropathy. The most frequently prescribed single
analgesic was morphine (52.2%); the most frequently prescribed two-drug combination was
morphine plus fentanyl (50.8%). Pethidine, however, was the most frequently prescribed anal-
gesic in the neurology (78.0%) and plastic surgery (50.0%) departments.
Conclusion: To decrease malaise and addiction in patients with CINCP, Taiwan’s physicians
need more education on narcotic analgesics, and greater professional cooperation to develop
therapeutic guidelines that will improve pain care for patients with CINCP.
Copyright ª 2015, Formosan Medical Association. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).ave no conflicts of interest relevant to this article.
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Chronic pain is a common and important medical problem
worldwide. The American Pain Society Clinical Guidelines1
define chronic noncancer pain as “back pain, osteoar-
thritis, fibromyalgia, and headache.” The United States
National Institutes of Health categorize pain as “acute pain,
chronic cancer pain, and chronic intractable noncancerTable 1 Demographic characteristics and diagnoses of patient
between 2003 and 2012.
Variablesa Male (n Z 398) Fe
n (%) n (
Age (y)b
19 4 (1.0)
20e29 28 (7.0) 1
30e39 117 (29.4) 4
40e49 126 (31.7) 6
50e59 47 (11.8) 3
60e69 33 (8.3) 2
70e79 30 (7.5) 3
80 13 (3.3) 2
Geographical areab
North 197 (50.1) 12
South 112 (28.5) 9
Central 64 (16.3) 2
East 20 (5.1)
Medical departmentb
Pain 214 (54.2) 15
Internal medicine 54 (13.7) 3
Other departmentsc 29 (7.4) 1
General surgery 30 (7.6) 1
Anesthesiology 24 (6.1) 1
Neurosurgery 17 (4.3) 1
Orthopedics 11 (2.8)
Plastic surgery 8 (2.0)
Neurology 8 (2.0)
Narcoticsb
Morphine 249 (55.0) 14
Fentanyl 70 (15.5) 6
Pethidine 63 (13.9) 3
Buprenorphine 39 (8.6) 2
Codeine 32 (7.1) 2
Opium 0 (0.0)
Type of pain diagnosedb
Neuropathy 136 (28.9) 7
Chronic pancreatitis 95 (20.2) 1
Other pain 29 (6.2) 4
FBSS 42 (8.9) 3
Fracture, osteoarthritis 38 (8.1) 3
Spinal cord injury 43 (9.1) 2
Low back pain 15 (3.2) 1
Autoimmune diseases 8 (1.7) 1
Hematological diseases 11 (2.3) 1
*p < 0.05.
FBSS Z failed back surgery syndrome.
a Each noncancer pain patient may be prescribed two or more opio
b c2 test.
c Other departments included urology, occupational and environmepain (CINCP),” all of which can affect physiological function
and produce adverse psychological effects such as depres-
sion and other negative emotions.
Patients with CINCP are treated primarily with narcotic
analgesics. To prevent iatrogenic addiction caused by
inappropriate long-term narcotic prescriptions for CINCP,
the Taiwan Food and Drug Administration (TFDA) has stip-
ulated clinical standards and guidelines for prescribings with CINCP (chronic intractable noncancer pain) in Taiwan
male (n Z 246) Total (N Z 644) p
%) N (%)
<0.001*
3 (1.2) 7 (1.1)
3 (5.3) 41 (6.4)
6 (18.7) 163 (25.3)
0 (24.4) 186 (28.9)
4 (13.8) 81 (12.6)
5 (10.2) 58 (9.0)
6 (14.6) 66 (10.2)
9 (11.8) 42 (6.5)
<0.001*
9 (51.4) 326 (50.6)
4 (37.5) 206 (32.0)
3 (9.2) 87 (13.5)
5 (2.0) 25 (3.9)
0.253
1 (60.6) 365 (56.7)
0 (12.0) 84 (13.0)
7 (6.8) 46 (7.2)
0 (4.0) 40 (6.2)
6 (6.4) 40 (6.2)
3 (5.2) 30 (4.7)
4 (1.6) 15 (2.3)
4 (1.6) 12 (1.9)
4 (1.6) 12 (1.9)
0.134
0 (47.9) 389 (52.2)
2 (21.2) 132 (17.7)
5 (12.0) 98 (13.2)
6 (8.9) 65 (8.7)
8 (9.6) 60 (8.1)
1 (0.3) 1 (0.1)
<0.001*
5 (27.7) 211 (30.7)
2 (4.4) 107 (15.6)
8 (17.7) 77 (11.2)
3 (12.2) 75 (10.9)
6 (13.3) 74 (10.8)
4 (8.9) 67 (9.7)
3 (4.8) 28 (4.1)
8 (6.6) 26 (3.8)
2 (4.4) 23 (3.3)
ids and might have two or more comorbid diseases.
ntal medicine, and obstetrics and gynecology.
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with CINCP and the CINCP prescriptions of physicians in
Taiwan. This information will be used to formulate national
policy for the long-term use of narcotic analgesics by pa-
tients with CINCP.Figure 1 Narcotic analgesics used in different age groups of
noncancer pain patients in Taiwan between 2003 and 2012.Methods
Patients
Sixty-six hospitals that were approved for long-term use of
narcotics to treat CINCP reported 644 new patients to the
TFDA’s Review and Approval Committee on Controlled
Drugs for Medical Use (RACCDMU) between 2003 and 2012.
That information was used for this study. Between 2003 and
2009, there were <100 new cases per year, but since 2010,
there have been >100 new cases per year. The patients
with CINCP were those not relieved from pain after they
had been given other medications or treatments; thus,
long-term narcotic analgesic formulations containing
morphine, codeine, pethidine, fentanyl, and buprenor-
phine were used. These patients had been diagnosed and
treated in regional or higher-level hospitals and reported to
the controlled drug review committee of that hospital for
approval, and then narcotic analgesics could be continued.
All hospitals in Taiwan are required to report to the TFDA
each case for which any narcotic analgesic is prescribed.Statistical analysis
Demographic characterizations and narcotic analgesics
prescribed by physicians were analyzed using the SPSS
version 18.0 software (SPSS Inc., Chicago, IL, USA). c2 tests
were used to compare sex and other categorical variables.
Significance was set at p < 0.05.Figure 2 Number of narcotic analgesics prescribed for pa-
tients with chronic intractable noncancer pain (CINCP) in
Taiwan between 2003 and 2012.Results
Most (61.8%) patients with CINCP were male; the mean age
for men was 45.9 years and that for women was 53.8 years
(Table 1). The highest percentage of narcotic analgesics
was used by men (31.7%) and women (24.4%) in the 40e49
years age group; however, a higher percentage of women
aged  50 years used them. A c2 test showed a significant
difference (p < 0.001) in age distribution between men and
women. Most of the patients with CINCP were from north-
ern Taiwan (male, 50.1%; female, 51.4%). The c2 test also
showed a significant (p < 0.001) difference between men
and women in geographical area. Most patients (male,
54.2%; female, 60.6%) were treated in the pain depart-
ment, but the sex distribution was not significantly
different. The prescribed narcotic analgesics were mainly
morphine (male, 55.0%; female, 47.9%), fentanyl (male,
15.5%; female, 21.2%), and pethidine (male, 13.9%; female,
12.0%), but the prescription percentages were not signifi-
cantly different by gender. The types of pain diagnosed
were primarily neuropathy (male, 28.9%; female, 27.7%),
chronic pancreatitis for men (20.2%), and fracture for
women (13.3%). A c2 test showed a significant (p < 0.001)difference between men and women in this category (Table
1).
Morphine was the most prescribed narcotic analgesic in
all age groups except for the 70e79 years age group, for
which fentanyl was most often prescribed. Fentanyl was
the second most prescribed. Pethidine was prescribed more
than fentanyl in the age groups 20e29 years, 30e39 years,
and 40e49 years, but for those who were aged <19 years
and 50 years fentanyl was prescribed more often than
pethidine (Figure 1). Buprenorphine was prescribed more
for those aged 50 years than for those aged 49 years,
and codeine was prescribed more for those who were aged
<19 years and 50 years.
For 81.0% of the cases, only one narcotic analgesic was
prescribed, and for 15.0% of the cases, two were prescribed
(Figure 2). The most prescribed one-drug regimens were
morphine (52.2%) and fentanyl (18.9%), and the most pre-
scribed two-drug regimens were morphine plus fentanyl
(50.8%), and then morphine plus pethidine (18.6%) or
buprenorphine (15.3%; Table 2).
Table 2 Narcotic analgesics prescribed for patients with chronic intractable noncancer pain (CINCP) in Taiwan between 2003
and 2012.a
One (n Z 581) Two (n Z 59) Three (n Z 4)
Narcotic
analgesic
% Narcotic
analgesic
Narcotic
analgesic
% Narcotic
analgesic
Narcotic
analgesic
Narcotic
analgesic
%
Morphine 52.2 Morphine Fentanyl 50.8 Morphine Fentanyl Buprenorphine 25.0
Fentanyl 18.9 Morphine Pethidine 18.6 Morphine Codeine Pethidine 50.0
Pethidine 10.5 Morphine Buprenorphine 15.3 Morphine Fentanyl Pethidine 25.0
Buprenorphine 10.3 Fentanyl Buprenorphine 1.7
Codeine 8.1 Fentanyl Pethidine 6.8
Morphine Codeine 3.4
Codeine Pethidine 3.4
a Every patient with CINCP may be prescribed more than one opioid.
776 I.-C. Cheng et al.The narcotic analgesics prescribed for patients with
CINCP varies by medical department, by physician, and by
patient. Morphine was most often prescribed in all de-
partments but neurology and plastic surgery, which most
often prescribed pethidine (78.0% and 50.0%, respectively;
Figure 3).Discussion
We found that the majority of our patients with CINCP were
male. According to TFDA statistics, from 1999 to 2007,
almost twice as many men (63.7%) as women (36.3%) with
CINCP were long-term narcotic analgesic users, indicating
that fewer women than men were treated for pain.2 Ac-
cording to Ho et al3 and Chang,4 more male than female
patients sought treatment. In addition, compared with
patients in general, patients with CINCP required moreFigure 3 Distribution of prescribed narcotic analgesics to the
different medical departments. Every patient with CINCP may betreatment and spent more on medication. Moreover, they
also reported that the differences between men and
women were significant (p < 0.001). Our findings support
their results. However, there is one study5 that reports a
higher prevalence of chronic pain in women than in men in
Taiwan. This inconsistency might be attributable to the
lower levels of physical strength and boneemuscle loading
in women than in men, hence the greater effect of chronic
pain.2 It is also possible that social, cultural, economic, and
political factors might have contributed to the lower per-
centage of women who asked for treatment.6
Chang4 showed that 15e44-year-old patients with CINCP
used more medical treatments than did older patients, and
Ho et al3 reported that 58% of 40e65-year-old patients with
CINCP were hospitalized; again, our findings support theirs.
The middle-aged population (somewhere between 40 years
old and 65 years old, depending on the source) is an
important workforce segment in society; thus, shouldpatients with chronic intractable noncancer pain (CINCP) in
prescribed more than one opioid.
Long-term use of narcotic analgesics 777CINCP affect the quality of life of this group of people, it
would cause a great loss in the workforce. Ho et al3 also
stated that the interference index of pain decreased from
8/10 to 4/10, which shows that narcotic analgesics signifi-
cantly reduced pain.
We found that most patients with CINCP had been
diagnosed with neuropathyde.g., postherpetic neuralgia
and diabetic neuropathydchronic pancreatitis, and failed
back surgery syndrome (FBSS), in that order. Postherpetic
neuralgia usually persists for >3 months and is extremely
difficult to treat. Because the mechanisms are complex and
involve the peripheral and central nervous systems, the
pain might manifest as burning, itching, and stabbing sen-
sations.7 Treatments include medication, laser therapy,
and nerve blocks.8 Regular treatment can control and
attenuate the symptoms of CINCP.
Chronic pancreatitis is characterized by the destruction
of pancreatic tissue structure and damage to the endocrine
and exocrine function, which is caused by intermittent
inflammation, and then develops into sustained chronic
pain. A previous study reported that the prevalence of
pancreatitis is w3.5e4/100,000 people per year, is most
frequent in 35e55-year-olds, and commonly causes severe
pain.9 Although patients with pancreatitis can be treated
with endoscopy or surgery, not all surgical procedures yield
significant improvement. If the pain seriously affects work
or social function, then long-term narcotic analgesics to
control the pain become necessary.
One study10 found that the failure rate for back surgery
has not declined in the past several decades. With
increasing rates of spine surgery, the number of patients
with FBSS has increased. In our study, FBSS accounted for
10% of patients with CINCP, which indicated that FBSS is one
of the major problems for which long-term narcotic anal-
gesics are used. Because only a few fully recover after back
surgery, narcotic analgesics were needed to relieve pain.
Another study11 reported that in 2249 (1.41%) of the
159,494 controlled inspections of cases involving narcotic
analgesics and psychotropic drugs that the TFDA made from
2002 to 2011, the percentage of inappropriate prescriptions
was even lower at 0.1%, which shows that the government
believes that the reasonable prescription of controlled
drugs is important. Regular inspections of inappropriate
prescriptions are made each year to reduce patient addic-
tion based on the long-term use of narcotic analgesics.
One study12 on the narcotic analgesics used in the United
States between 1997 and 2007 reported that morphine was
the most popular, that the popularity of morphine and
fentanyl combined was increasing, and that the popularity
of pethidine was decreasing. A similar study in Taiwan13
also reported that between 2002 and 2011, the popularity
of morphine and fentanyl combined was increasing,
whereas the popularity of pethidine was decreasing.
In Taiwan, the third most widely used narcotic analgesic
for pain relief in patients with CINCP was pethidine, which
is addictive. Its pain-relieving effect was not better than
other narcotic analgesics according to pharmacological
studies. Moreover, because its active metabolite, norpe-
thidine (normeperidine), is a neurotoxin, using pethidine
long term can cause adverse side effects such as seizures.
Advanced countries in Europe and America have excluded
pethidine as a first-line drug. In 2011, the TFDA publishedpethidine clinical guidelines for Taiwan.14 These guidelines
mention pethidine abuse and addiction caused by inap-
propriate use in Taiwan and other countries. Cross analysis
of the departments and drug prescriptions in our study
showed that pethidine was most often used in the de-
partments of internal medicine, general surgery, neurology,
and plastic surgery. According to the clinical guidelines,
pethidine is indicated in only a few contexts.14 Pethidine is
easily abused and should never be taken with alcohol or
other opioids.15
The American Society of Interventional Pain Physicians
developed a guide for using opioids for CINCP drugs.16 It
established a policy for physicians and the legal sector in
the United States. The United States Drug Enforcement
Agency pointed out that physicians should fully understand
narcotic analgesics. In clinical situations, if narcotic anal-
gesics are indicated as the best treatment for pain, then
the drug should be provided to relieve the pain of the pa-
tient.17 The American Chronic Pain Association (ACPA)
published the ACPA Resource Guide to Chronic Pain Medi-
cation & Treatment18 in 2014 to offer patients drug-related
information to “relieve the fears that can interfere with
receiving maximum benefits from such treatment and
medications. Information can also prevent unrealistic ex-
pectations that can lead to disappointment or even worse,
a bad outcome.”18 The American Pain Society and the
American Academy of Pain Medicine systematically
reviewed evidence and convened multidisciplinary expert
meetings on pain management.1 The recommendations
presented in these clinical guidelines for using long-term
opioid therapy to attenuate CINCP provide (1) patient se-
lection and risk stratification, (2) informed consent and
opioid management plans; explain how to (3) initiate and
titrate long-term opioid therapy, (4) use methadone, (5)
monitor patients on long-term opioid therapy, (6) prevent
and manage opioid-related adverse effects, (7) use chronic
opioid therapy in pregnancy; and discuss (8) dose escala-
tions, (9) driving and work safety, (10) identifying a medical
home and when to obtain consultation, and (11) managing
breakthrough pain.1
Unlike most other countries, the TFDA has published a
user guide for using narcotic analgesics in medical practice
and issues reference announcements on opioid pre-
scriptions for physicians. A study19 on narcotic analgesic use
in two medical centers in Taiwan reports that most physi-
cians not specialized in anesthesiology, including those in
surgery, internal medicine, oncology, and other specialties,
are not sufficiently knowledgeable about narcotic analge-
sics and have negative attitudes about using them. Thus,
they concluded that it is necessary to strengthen Taiwan
physician education about pain medicine so that patients
with CINCP can be properly cared for. In Taiwan, Schedule 1
and Schedule 2 narcotics can be manufactured or imported
only by the TFDA. In the future, new ingredients and new
formulations of narcotic analgesics from abroad can be
introduced in Taiwan at the proper time, to offer physicians
a better choice of prescriptions for patients with CINCP, to
improve treatment quality, to reach effective pain control,
and to protect patient health.
The TFDA user guide is a reference for legal institutions
such as the courts and for physicians. In most other coun-
tries, standards are set by professional societies,
778 I.-C. Cheng et al.associations, or councils. In the future, Taiwan can also
follow the latter model and, in cooperation with these
groups of medical professionals, develop a more compre-
hensive guide and reeducate physicians and the general
public.
The data in this study were collected from medical
institution reports to the TFDA. The cases were limited to
patients with a first-reported new diagnosis of CINCP. These
patients were also Review and Approval Committee on
Controlled Drugs for Medical Use-approved long-term users
of narcotic analgesics, which might not be representative
of the general situation throughout Taiwan nor account for
patients weaned off opioids or lost to follow-up. In addi-
tion, the data entered by medical staff might be incom-
plete owing to missing values.
This study is one of a few conducted on the national
CINCP data analysis in recent years. Although the variables
were limited, the findings offer a full picture of current
patients with CINCP in Taiwan. The major patient group is
male, middle-aged, living in northern Taiwan, treated pri-
marily in a department of pain, has a major diagnosis of
underlying neuropathy, and has most likely been prescribed
morphine. It is necessary to strengthen cautionary state-
ments and health education to patients, to offer necessary
drug-use counseling, and to reduce the negative side ef-
fects of depression and opioid addiction in patients. Phy-
sicians need more education about prescribing narcotic
analgesics, and need to cooperate more with groups of
medical professionals to develop guidelines and manuals
that will strengthen their ability to provide adequate care
to patients with CINCP. Because only limited narcotic an-
algesics are available in Taiwan, new gradients and new
drug formulations should be introduced when necessary, to
offer more choices to physicians who treat patients with
CINCP. To improve pain management and the quality of
patient care, the public, too, needs to be educated about
narcotic analgesics. In addition, our opioid management
regulations should be updated to the new standards
developed in other countries so that we can teach both our
physicians and patients about the positive and negative
impact of narcotic analgesics for treating CINCP. More
thorough epidemiological studies are needed to understand
more about patients with CINCP.
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